JP2021521266A5 - - Google Patents
Info
- Publication number
- JP2021521266A5 JP2021521266A5 JP2020569776A JP2020569776A JP2021521266A5 JP 2021521266 A5 JP2021521266 A5 JP 2021521266A5 JP 2020569776 A JP2020569776 A JP 2020569776A JP 2020569776 A JP2020569776 A JP 2020569776A JP 2021521266 A5 JP2021521266 A5 JP 2021521266A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- compound according
- groups
- optionally substituted
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670323P | 2018-05-11 | 2018-05-11 | |
| US62/670,323 | 2018-05-11 | ||
| PCT/US2019/032043 WO2019217972A1 (en) | 2018-05-11 | 2019-05-13 | Kdm1a inhibitors for the treatment of disease |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021521266A JP2021521266A (ja) | 2021-08-26 |
| JPWO2019217972A5 JPWO2019217972A5 (https=) | 2022-05-16 |
| JP2021521266A5 true JP2021521266A5 (https=) | 2022-05-16 |
| JP7450559B2 JP7450559B2 (ja) | 2024-03-15 |
Family
ID=68468431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569776A Active JP7450559B2 (ja) | 2018-05-11 | 2019-05-13 | 疾患の処置のためのｋｄｍ１ａ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11578059B2 (https=) |
| EP (1) | EP3790867B1 (https=) |
| JP (1) | JP7450559B2 (https=) |
| KR (1) | KR102684364B1 (https=) |
| CN (1) | CN112513020B (https=) |
| AU (1) | AU2019265022B2 (https=) |
| BR (1) | BR112021001066A2 (https=) |
| CA (1) | CA3103392A1 (https=) |
| ES (1) | ES2977656T3 (https=) |
| IL (1) | IL279260B2 (https=) |
| PH (1) | PH12020552135A1 (https=) |
| SG (1) | SG11202012289UA (https=) |
| WO (1) | WO2019217972A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2734209T3 (es) | 2013-08-06 | 2019-12-04 | Imago Biosciences Inc | Inhibidores de KDM1A para el tratamiento de enfermedades |
| PL3256218T3 (pl) | 2015-02-12 | 2025-03-31 | Imago Biosciences Inc. | Inhibitor kdm1a i jego zastosowanie w terapii |
| WO2018035259A1 (en) | 2016-08-16 | 2018-02-22 | Imago Biosciences, Inc. | Methods and processes for the preparation of kdm1a inhibitors |
| BR112021001066A2 (pt) | 2018-05-11 | 2021-04-20 | Imago Biosciences, Inc. | composto, método de tratamento de uma doença mediada por kdm1a, método de tratamento de uma doença mediada por globina, composição farmacêutica; método de inibição de kdm1a, método para obter um efeito em um paciente, e método para inibir pelo menos uma função de kdm1a |
| IL293703A (en) * | 2019-12-09 | 2022-08-01 | Imago Biosciences Inc | Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms |
| CN117062813A (zh) * | 2021-03-24 | 2023-11-14 | 四川汇宇制药股份有限公司 | 一种多环化合物及其应用 |
| CN114591324B (zh) * | 2021-03-30 | 2023-05-05 | 深圳微芯生物科技股份有限公司 | 一类吡嗪酮衍生物、其制备及其应用 |
| JP2024513260A (ja) | 2021-04-08 | 2024-03-22 | オリゾン ジェノミックス ソシエダッド アノニマ | 骨髄癌処置のためのｌｓｄ１阻害剤の組み合わせ |
| CN119546292A (zh) | 2022-05-09 | 2025-02-28 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法 |
| JP2025516648A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| US20260085082A1 (en) * | 2022-12-23 | 2026-03-26 | Imago Biosciences, Inc. | Kdm1a inhibitors for the treatment of disease |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0515896A (pt) * | 2004-09-24 | 2008-08-12 | Idenix Cayman Ltd E Ct Nat De | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| EP2170848B1 (en) * | 2007-06-27 | 2014-10-22 | AstraZeneca AB | Pyrazinone derivatives and their use in the treatment of lung diseases |
| KR101586503B1 (ko) | 2007-09-13 | 2016-01-18 | 코덱시스, 인코포레이티드 | 아세토페논의 환원을 위한 케토리덕타제 폴리펩티드 |
| WO2009046153A1 (en) | 2007-10-01 | 2009-04-09 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
| US8288141B2 (en) | 2008-08-27 | 2012-10-16 | Codexis, Inc. | Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| EP2177502A1 (en) | 2008-10-17 | 2010-04-21 | Oryzon Genomics, S.A. | Compounds and their use |
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| US8415381B2 (en) * | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| RU2602814C2 (ru) | 2009-09-25 | 2016-11-20 | Оризон Дженомикс С.А. | Лизинспецифические ингибиторы деметилазы-1 и их применение |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| RS55348B1 (sr) | 2010-04-19 | 2017-03-31 | Oryzon Gnomics S A | Inhibitori lizin specifične demetilaze-1 i njihova upotreba |
| CN102985402B (zh) | 2010-04-20 | 2015-04-29 | 罗马大学 | 反苯环丙胺衍生物作为组蛋白去甲基酶lsd1和/或lsd2的抑制剂 |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012013728A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
| US9527805B2 (en) | 2010-09-10 | 2016-12-27 | Robert A. Casero | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US20120108500A1 (en) | 2010-10-07 | 2012-05-03 | Naoki Sakane | Compositions and Methods for Modulating Immunodeficiency Virus Transcription |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| US20140163041A1 (en) | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| EA023143B1 (ru) | 2011-03-25 | 2016-04-29 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Замещенный циклопропиламин в качестве ингибитора lsd1 |
| KR20140052018A (ko) | 2011-08-09 | 2014-05-02 | 다케다 야쿠힌 고교 가부시키가이샤 | 시클로프로판아민 화합물 |
| MX356344B (es) | 2011-10-20 | 2018-05-23 | Oryzon Genomics Sa | Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1. |
| RU2668952C2 (ru) | 2011-10-20 | 2018-10-05 | Оризон Дженомикс, С.А. | (гетеро)арилциклопропиламины в качестве ингибиторов lsd1 |
| EP2927212A4 (en) | 2012-11-28 | 2016-06-08 | Univ Kyoto | LSD1-SELECTIVE HEMMER WITH LYSINE STRUCTURE |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| WO2014164867A1 (en) * | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| CA2916533C (en) | 2013-06-25 | 2022-12-20 | University Of Canberra | Methods and compositions for modulating cancer stem cells |
| ES2734209T3 (es) * | 2013-08-06 | 2019-12-04 | Imago Biosciences Inc | Inhibidores de KDM1A para el tratamiento de enfermedades |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| EP3134519B1 (en) | 2014-04-22 | 2018-06-06 | c-LEcta GmbH | Ketoreductases |
| RS60658B1 (sr) * | 2014-06-27 | 2020-09-30 | Celgene Quanticel Research Inc | Inhibitori lizin specifične demetilaze-1 |
| PL3256218T3 (pl) | 2015-02-12 | 2025-03-31 | Imago Biosciences Inc. | Inhibitor kdm1a i jego zastosowanie w terapii |
| WO2017075367A1 (en) * | 2015-10-28 | 2017-05-04 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
| WO2017079753A1 (en) | 2015-11-05 | 2017-05-11 | Imago Biosciences, Inc. | Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms |
| JP6916795B2 (ja) * | 2015-12-29 | 2021-08-11 | ミラティ セラピューティクス， インコーポレイテッド | Ｌｓｄ１阻害剤 |
| KR102479789B1 (ko) * | 2016-05-09 | 2022-12-22 | 주빌런트 에피코어 엘엘씨 | 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물 |
| US20220025424A1 (en) | 2016-08-16 | 2022-01-27 | Imago Biosciences, Inc. | Compositions and methods for producing stereoisomerically pure aminocyclopropanes |
| WO2018035259A1 (en) | 2016-08-16 | 2018-02-22 | Imago Biosciences, Inc. | Methods and processes for the preparation of kdm1a inhibitors |
| US20200069677A1 (en) | 2016-12-09 | 2020-03-05 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| BR112021001066A2 (pt) | 2018-05-11 | 2021-04-20 | Imago Biosciences, Inc. | composto, método de tratamento de uma doença mediada por kdm1a, método de tratamento de uma doença mediada por globina, composição farmacêutica; método de inibição de kdm1a, método para obter um efeito em um paciente, e método para inibir pelo menos uma função de kdm1a |
-
2019
- 2019-05-13 BR BR112021001066-1A patent/BR112021001066A2/pt unknown
- 2019-05-13 CN CN201980046308.0A patent/CN112513020B/zh active Active
- 2019-05-13 IL IL279260A patent/IL279260B2/en unknown
- 2019-05-13 SG SG11202012289UA patent/SG11202012289UA/en unknown
- 2019-05-13 US US17/054,126 patent/US11578059B2/en active Active
- 2019-05-13 AU AU2019265022A patent/AU2019265022B2/en active Active
- 2019-05-13 KR KR1020207035544A patent/KR102684364B1/ko active Active
- 2019-05-13 WO PCT/US2019/032043 patent/WO2019217972A1/en not_active Ceased
- 2019-05-13 JP JP2020569776A patent/JP7450559B2/ja active Active
- 2019-05-13 EP EP19800758.5A patent/EP3790867B1/en active Active
- 2019-05-13 ES ES19800758T patent/ES2977656T3/es active Active
- 2019-05-13 CA CA3103392A patent/CA3103392A1/en active Pending
-
2020
- 2020-12-11 PH PH12020552135A patent/PH12020552135A1/en unknown
-
2022
- 2022-12-15 US US18/066,667 patent/US11932629B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521266A5 (https=) | ||
| CN111971279B (zh) | 趋化因子受体调节剂及其用途 | |
| RU2768827C2 (ru) | Модуляторы хемокинового рецептора и их применение | |
| ES2841912T3 (es) | Inhibidores de CXCR2 | |
| ES2657839T3 (es) | Compuestos de pirazolopirimidina inhibidores de JAK y métodos | |
| ES2712973T3 (es) | Inhibidores de MDM2 y métodos terapéuticos que usan los mismos | |
| JP7184889B2 (ja) | 統合的ストレス経路の調節剤 | |
| KR20250029954A (ko) | 피리도[4,3-d]피리미딘 화합물 | |
| JP5760010B2 (ja) | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 | |
| ES2910071T3 (es) | Compuestos de aminopirazina diol como inhibidores de PI3K-Y | |
| JP6382831B2 (ja) | アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト | |
| JP2025114615A (ja) | 治療薬としての細胞毒素のペプチドコンジュゲート | |
| RU2016118768A (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
| EP3996711B1 (en) | Indanes as pd-l1 inhibitors | |
| JP2021501788A (ja) | 統合的ストレス経路の調節剤 | |
| ES2715104T3 (es) | Nuevos derivados de pirazolopirimidina como inhibidores de nik | |
| JP2021501780A (ja) | 統合的ストレス経路の調節剤 | |
| CN106488910A (zh) | Kras g12c的抑制剂 | |
| JP2016525529A5 (https=) | ||
| EA032639B1 (ru) | Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида | |
| JPWO2019217972A5 (https=) | ||
| RU2016106003A (ru) | Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| US12006320B2 (en) | Heterocyclic derivatives as PI3K inhibitors | |
| KR20250100539A (ko) | 피리도[4,3-d]피리미딘 화합물 | |
| BR112020001949A2 (pt) | composto, composição farmacêutica, e, métodos para tratar um linfoma não hodgkin e para tratar um linfoma ou uma leucemia |